Showing results (1651-1660 of 2,232) with videos related to
Sort By:
Pageof 224
Oncogene|June 28, 2016
p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNAL-Z Xu, S-S Li, W Zhou, et al.Bioorganic & Medicinal Chemistry Letters|May 20, 2004
3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3Han-Cheng Zhang, Hong Ye, Bruce R Conway, et al.Clinical Genitourinary Cancer|March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 TrialsPatrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 28, 2022
[Retrospective analysis of short-term curative effect of total laparoscopic loop ileostomy reversal after radical resection of rectal cancer]S Luo, H Su, Z Xu, et al.Physical Review Letters|August 16, 2011
All-optical cascaded laser wakefield accelerator using ionization-induced injectionJ S Liu, C Q Xia, W T Wang, et al.Cell Death & Disease|March 24, 2017
Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathwayJ Y Liu, Y B Dai, X Li, et al.Leukemia|April 9, 2016
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cellsZ Xu, P P Sharp, Y Yao, et al.Redox Biology|March 12, 2023
Release of hepatic xanthine oxidase (XO) to the circulation is protective in intravascular hemolytic crisisHeidi M Schmidt, Evan R DeVallance, Sara E Lewis, et al.Blood|May 16, 2022
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Z Xu, Anna Conrey, Ingrid Frey, et al.Current Oncology (Toronto, Ont.)|June 23, 2016
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancerB Melosky, J Agulnik, R Albadine, et al.Pageof 224